Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06233370 · ClinicalTrials.gov registry record · Early Phase 1

Acute Effects of Walking Exercise on Brain Functioning in Multiple Sclerosis

A Early Phase 1 study of Multiple Sclerosis, sponsored by Kessler Foundation.

Active
Registry status
Early Phase 1
Development phase
24
Enrollment target
1
Study location

NCT06233370 is a Early Phase 1 study of Multiple Sclerosis that is active but no longer recruiting, run by Kessler Foundation. The registered enrollment target is 24 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06233370, a Early Phase 1 study of Multiple Sclerosis, is active but no longer recruiting, sponsored by Kessler Foundation.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The project will involve a within-subjects, repeated-measures research design. Participants will initially be screened for relevant inclusion/exclusion criteria for maximizing safety of participating in an exercise study. If a participant meets those inclusion/exclusion criteria, they will visit Kessler Foundation three times. The first visit will involve a baseline session where participants will complete several cognitive tests. This will be followed by a training session, where participants will be provided with a FitBit, and will be trained by research staff to walk at a rate of 100 steps per minute. Once participants demonstrate proficiency at walking at this rate using the FitBit, participants will complete several questionnaires, followed by a maximal, graded exercise test to determine cardiorespiratory fitness. One week later, participants will return to Kessler Foundation to complete 1 of 2 experimental sessions that will be delivered in a random order that further will be counterbalanced across participants (to minimize the potential effects of session order on brain function and blood flow, respectively). Both experimental sessions will follow the same structure. First, participants will undertake a 30-minute MRI scan at Kessler Foundation to measure brain function and brain blood flow. Immediately following the MRI scan, participants will engage in either 20 minutes of treadmill walking exercise or 20 minutes of overground walking exercise at a rate of 100 steps per minute. Immediately following the 20-minute exercise bouts, participants will undertake another MRI scan for measuring brain function and brain blood flow. Participants will return to Kessler Foundation a third time to complete the opposite experimental session that was not completed during the second visit (i.e., overground walking exercise if treadmill walking exercise was completed during the second visit). In total, each participant will undergo four MRI scans over the course of the study

Conditions Studied

Interventions

  • BEHAVIORAL Moderate intensity walking exercise

Study Locations (1)

New Jersey

  • Kessler Foundation - West Orange

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2024-03-01
Est. Completion 2025-12-31
Phase Early Phase 1

Sponsor

Kessler Foundation

104 total trials

What the Registry Record Tells You About NCT06233370

The ClinicalTrials.gov registry entry for NCT06233370 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower). The listed sponsor is Kessler Foundation, which has 104 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Moderate intensity walking exercise is the first listed.

NCT06233370 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT06233370 about?

NCT06233370 is a clinical study titled "Acute Effects of Walking Exercise on Brain Functioning in Multiple Sclerosis". The project will involve a within-subjects, repeated-measures research design. Participants will initially be screened for relevant inclusion/exclusion criteria for maximizing safety of participating in an exercise study. If a participant meets those inclusion/exclusion criteria, they will visit Kes...

What is the current status of trial NCT06233370?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2024-03-01. Estimated completion is 2025-12-31.

What conditions does trial NCT06233370 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT06233370?

The interventions under investigation include: Moderate intensity walking exercise (BEHAVIORAL).

Who is sponsoring clinical trial NCT06233370?

This trial is sponsored by Kessler Foundation, which has 104 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06233370 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.